Contents

Search

triple negative breast cancer; (ER-, PR-, HER2-)

Epidemiology: - black women twice as likely as white women to be diagnosed with triple-negative breast cancer [3] - they are also more likely to die from the disease [3] Pathology: - TRIM37 is a driver of triple-negative breast cancer metastasis & resistance to chemotherapy - TRIM37 point mutation variant rs57141087 is predominant in Black women & modulates TRIM37 levels through enhancer-promoter interactions - TRIM37 overexpression in early stages of triple-negative breast cancer promotes neoplastic transformation, accelerates tumor growth & drives metastases [3] Management: - triple negative (ER/PR receptor negative, HER2 negative) breast cancer responds to neoadjuvant chemothrapy [1] - anthracycline-base chemotherapy for early stage triple-negative breast cancer (ER-, PR-, HER2-) [1] - neoadjuvant chemotherapy for triple negative tumors uses standard chemotherapy (see chemotherapy for breast cancer) [1] - atezolizumab (Tecentriq) FDA-approved for treatment of unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1 [2] - targeting TRIM37 using nanoparticle delivery mechanisms is pending [3] - also see breast cancer

General

breast cancer

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 18.
  2. FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm
  3. Winn S UC Davis researchers help decode the cause of aggressive breast cancer in women of color. Cancer Care. December 20, 2024 https://health.ucdavis.edu/news/headlines/uc-davis-researchers-help-decode-the-cause-of-aggressive-breast-cancer-in-women-of-color/2024/12